{"prompt": "['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 20 of 129', 'Duration of', \"Each subject's trial participation will be up to approximately 52 weeks:\", 'treatment', 'screening period (including wash-out, if applicable) up to 6 weeks, treatment', 'period of 32 weeks, and follow-up period of 14 weeks (subjects may enter the', 'long-term extension trial [LP0162-1337, ECZTEND], at any time during the', 'safety follow-up period).', 'Number of subjects', 'A total of 369 subjects will be randomised 2:1 to treatment (246 subjects to', 'to be enrolled', 'tralokinumab; 123 subjects to placebo).', 'Number and', 'Approximately 70 sites in Europe and North America.', 'distribution of trial', 'sites', 'Statistical methods', 'Primary endpoints', 'The difference in response rates between treatment groups will be analysed', 'using the Cochran-Mantel-Haenszel test stratified by region and baseline', 'disease severity. Subjects with missing data or subjects who receive rescue', 'medication prior to the Week 16 visit will be considered as non-responders in', 'the analysis.', 'The primary endpoints will be tested sequentially at a 5% significance level.', 'First IGA 0/1 and, if significant, EASI75. If both primary null hypotheses are', 'rejected, the secondary endpoints will be tested.', 'Secondary endpoints', 'The change from baseline to Week 16 in SCORAD will be analysed using a', 'repeated measurements model on the post baseline responses up to Week 16.', 'Reduction of Worst Daily Pruritus NRS weekly average of at least 4 from', 'baseline to Week 16 is a binary endpoint, and as such it will be analysed as', 'described for the primary endpoints.', 'Change from baseline to Week 16 in DLQI will be analysed the same way as', 'change in SCORAD.', 'The secondary endpoints will be tested using the Holm method for multiplicity', 'adjustment hereby controlling the overall type 1 error rate for the trial.', 'International', 'Associate Professor Jonathan Silverberg, MD, PhD, MPH, Departments of', 'coordinating', 'Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern', 'investigator', 'University Feinberg School of Medicine, United States.', \"Sponsor's name/\", 'LEO Pharma A/S, Industriparken 55, DK-2750 Ballerup, Denmark', 'address', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 21 of 129', '2 Trial identification', 'EudraCT number: 2017-002065-21', 'IND number: 123,797', 'ClinicalTrials.gov number: NCT03363854', '3 Schematic of trial design', 'Panel 1 Trial design', 'Tralokinumab 300mg+TCS', 'Placebo+TCS', 'Screening and Follow-up Visits', 'Trial Period', 'Screening', 'Initial Treatment', 'Continuation Treatment', 'Follow-up', 'Washout of TCS and', 'tralokinumab Q2W TCS', 'Re-randomisation at Week 16', 'Off-treatment period', 'other AD medication', 'or placebo Q2W TCS', '16w responders', '2:1 randomisation', '1:1 re-rando of responders to', 'tralokinumab Q2W+TCS or Q4W+TCS', 'Tralokinumab', '300mg', '246 patients', '+TCS', 'every 2nd week after', '600mg loading', '16w non-responders', 'tralokinumab Q2W+TCS', '16w non-responders', 'Placebo', '123 patients', 'tralokinumab Q2W+TCS', 'TCS', 'every 2nd week after', '16w responders', 'loading', 'placebo Q2W+TCS', 'Primary Endpoint', 'Visit No. 1', '3', '11', '19', '20', '-6w', '0', '16w', '32w', '46w', 'Weeks from start of treatment', 'Abbreviations: AD, atopic dermatitis; No, number; re-rando, re-randomisation; Q2W, every 2 weeks;', 'Q4W, every 4 weeks; TCS, topical corticosteroids; W, week.', \"Note: Clinical response is defined as subjects achieving Investigator's Global Assessment response of 0 (clear)\", 'or 1 (almost clear) or at least 75% reduction in Eczema Area and Severity Index.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}